• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
5.88% 18.0¢

PHARMAUST LIMITED - News & Media

Market Cap $87.55M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

PharmAust is a clinical-stage biotechnology company developing new therapeutics for human... PharmAust is a clinical-stage biotechnology company developing new therapeutics for human health. The Company's segments include Corporate and Research. The Company is focused on repurposing monepantel for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis (ALS) - the most common form of motor neurone disease (MND). The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway which plays a central role in cell growth and proliferation and in degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease. The company successfully completed a Phase 1 study in monepantel as a treatment for ALS/MND with encouraging results. Monepantel has subsequently been accepted into the prestigious HEALEY ALS Platform Trial in the US. The company anticipates starting the Phase 2/3 study in H2 2024.More

Articles & Videos

PharmAust reappoints MD and resets its sights on MND battle

Biotechnical company PharmAust has reappointed Dr Michael Thurn as Managing Director and and Dr Nicky Wallis as Chief Scientific Officer.

31 May 2024 09:28 (AEST)

PharmAust CEO's sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.

23 Apr 2024 12:08 (AEST)

PharmAust teams up with Berry Consultants for phase 2/3 MND study

PharmAust (ASX:PAA) is collaborating with renowned clinical study design expert, Berry Consultants, to design and analyse its planned phase 2/3 study for monepantel in patients with MND and ALS.

16 Jan 2024 13:34 (AEDT)

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel (MPL) to test its functions on Motor Neuron Disease (MND).

01 Dec 2023 11:32 (AEDT)

PharmAust completes dosing in phase one MND trial

Pharmaust (ASX:PAA) has finished dosing all patients in cohort four of its phase one MEND study using monepantel (MPL) to treat Motor Neurone Disease.

13 Oct 2023 10:50 (AEDT)

PharmAust (ASX:PAA) welcomes Dr Michael Thurn as new CEO

PharmAust (ASX:PAA) has appointed Dr Michael Thurn as its newest Chief Executive Officer, starting from September 1.

28 Aug 2023 15:09 (AEST)

PharmAust's (ASX:PAA) phase one trial indicates MPL's potential to slow MND progression

Pharmaust (ASX:PAA) has reported that its phase one trial using the lead drug, MPL, for MND/ALS has successfully slowed disease progression in 11 out of 12 patients.

22 Aug 2023 11:41 (AEST)

PharmAust's (ASX:PAA) subsidiary Epichem enters voluntary liquidation

PharmAust (ASX:PAA) has appointed joint and several liquidators from Grant Thornton Australia, to administer the creditor's voluntary winding-up proceedings for PAA's subsidiary, Epichem.

01 Aug 2023 13:39 (AEST)

PharmAust's (ASX:PAA) Beagle patient surpasses one year on MPL

PharmAust’s (ASX:PAA) patient, Louie the Beagle, has surpassed one year of treatment with the company’s Monepantel (MPL) drug.

06 Jul 2023 13:42 (AEST)

PharmAust (ASX:PAA) reports positive preliminary data in MND/ALS trial

PharmAust (ASX:PAA) has released preliminary data from its phase 1/2 trial assessing its lead drug candidate MPL in MND/ALS0.

04 Jul 2023 16:25 (AEST)



(20min delay)
Last
18.0¢ 		Change
0.010(5.88%) 		Mkt cap ! $87.55M
Open High Low Value Volume
17.0¢ 18.0¢ 17.0¢ $36.1K 210.8K

Buyers (Bids)

No. Vol. Price($)
1 58823 17.0¢
 

Sellers (Offers)

Price($) Vol. No.
18.0¢ 154996 3
View Market Depth
Last trade - 16.10pm 20/09/2024 (20 minute delay) ?
Last
17.0¢ 		  Change
0.010 ( 1.49 %)
Open High Low Volume
16.5¢ 17.5¢ 16.5¢ 246876
Last updated 15.23pm 20/09/2024 ?
PAA (ASX) Chart

Top Stories

Tennant Minerals clocks high-grade gold, copper hits at Bluebird in the NT

Tennant Minerals has unveiled the results of its latest drill campaign at its Bluebird project, posting "high-grade" copper and gold hits.
Harvey Norman hit with a second class action – and shareholders, once again, don't care Harvey Norman (ASX:HVN) has confirmed it's been hit by a second class action this week over allegedly dodgy warranty cover – and the stock is up +1.23 at 11.15am Sydney time.
Drilling shows continuous Cu mineralisation at Whundo for Greentech Greentech Metals Ltd has rolled out an extensive drilling program at the Whundo copper-zinc project 40 kilometres from Karratha
Catalina Resources kicks off aircore drilling at Laverton project on the hunt for gold, REEs Catalina Resources has confirmed its latest drill run has kicked off on-site its Laverton Project in Western Australia's Northern Goldfields.
Develop Global appoints GR to get Woodlawn copper-zinc plant online mid-2025 Develop shares jumped just over 4% in lunchtime trades on Friday as the company sees mid-2025 Woodlawn start.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.